Plus Therapeutics Study Shows Early Detection Can Reduce Healthcare Costs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PSTV?
Source: Globenewswire
- Economic Impact Analysis: Plus Therapeutics' study indicates that earlier diagnosis and therapeutic management of leptomeningeal metastases (LM) using the CNSide cerebrospinal fluid assay can reduce related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention and improved treatment precision, significantly alleviating the financial burden on patients.
- Clinical Data Support: The research highlights that late-stage LM patients incur median inpatient costs of about $20,000, with total related costs potentially exceeding $100,000 per month, underscoring the critical importance of early detection to lower healthcare expenditures and improve patient outcomes.
- Conference Presentation: The findings will be presented at the ISPOR 2026 Annual Meeting, which gathers global experts in health economics and outcomes research, further promoting the recognition of CNSide's clinical and economic value and facilitating its commercialization in the United States.
- Innovative Treatment Solutions: REYOBIQ, a novel radiotherapy targeting CNS tumors, offers enhanced targeting and safety, currently undergoing multiple clinical trials, demonstrating potential therapeutic advantages for difficult-to-treat cancers, thereby strengthening the company's competitive position in this sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSTV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSTV
Wall Street analysts forecast PSTV stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.250
Low
2.00
Averages
8.00
High
19.00
Current: 0.250
Low
2.00
Averages
8.00
High
19.00
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Plus Therapeutics Study Shows Early Detection Can Reduce Healthcare Costs
- Economic Impact Analysis: Plus Therapeutics' study indicates that earlier diagnosis and therapeutic management of leptomeningeal metastases (LM) using the CNSide cerebrospinal fluid assay can reduce related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention and improved treatment precision, significantly alleviating the financial burden on patients.
- Clinical Data Support: The research highlights that late-stage LM patients incur median inpatient costs of about $20,000, with total related costs potentially exceeding $100,000 per month, underscoring the critical importance of early detection to lower healthcare expenditures and improve patient outcomes.
- Conference Presentation: The findings will be presented at the ISPOR 2026 Annual Meeting, which gathers global experts in health economics and outcomes research, further promoting the recognition of CNSide's clinical and economic value and facilitating its commercialization in the United States.
- Innovative Treatment Solutions: REYOBIQ, a novel radiotherapy targeting CNS tumors, offers enhanced targeting and safety, currently undergoing multiple clinical trials, demonstrating potential therapeutic advantages for difficult-to-treat cancers, thereby strengthening the company's competitive position in this sector.
See More
Plus Therapeutics Releases 2026 Milestones and Financial Results
- Financial Performance: Plus Therapeutics reported a FY GAAP EPS of -$0.29, beating expectations by $0.01, while revenue of $5.21M, down 10.5% year-over-year, still exceeded forecasts by $0.14M, indicating resilience amid challenges.
- Clinical Trial Progress: The company anticipates reporting optimal dosing and interval data for REYOBIQ in the ReSPECT-LM Phase 2 trial in Q3 2026, laying the groundwork for future clinical applications and enhancing market competitiveness.
- FDA Meeting Arrangement: Plus Therapeutics will complete enrollment in the ReSPECT-GBM Phase 2 trial and conduct an End of Phase meeting with the FDA, aiming to align on pivotal trial design, with data expected in Q4 2026 that could influence future drug approval processes.
- Manufacturing Scale-Up: The company plans to complete the commercial manufacturing scale-up for REYOBIQ and begin enrollment in the ReSPECT-PBC pediatric brain cancer Phase 1 trial, marking a strategic expansion into pediatric oncology and further strengthening its product portfolio.
See More
Plus Therapeutics Receives AMA Approval for New CPT Code
- CPT Code Approval: The American Medical Association has approved the CPT code X566T for tracking the use of REYOBIQ in recurrent glioblastoma and pediatric brain cancer, marking a significant advancement in market access for this innovative treatment, which is expected to enhance clinical application and reimbursement prospects.
- Clinical Trial Progress: Plus Therapeutics is on track to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting to align on pivotal trial design, demonstrating the company's commitment to advancing clinical research.
- Funding Support: The clinical trials for REYOBIQ are supported by grants from the National Cancer Institute and a $17.6 million three-year grant from the Cancer Prevention & Research Institute of Texas, indicating strong recognition and backing from the research community.
- Market Potential: As a novel radiotherapy, REYOBIQ has the potential to improve treatment outcomes for CNS tumors, particularly where conventional therapies fail, further solidifying the company's market position in this critical area.
See More
Plus Therapeutics (PSTV) Outlines 2026 Goals to Advance REYOBIQ and Expand CNSide Platform
- Funding Support: Plus Therapeutics has completed a $15 million upsized offering aimed at accelerating the REYOBIQ clinical program and the commercialization of the CNSide diagnostic platform, thereby extending its cash runway through 2027 to ensure ongoing operations during critical development phases.
- Clinical Trial Progress: The REYOBIQ ReSPECT-LM and ReSPECT-GBM Phase 2 trials are set to report data in Q3 and Q4 2026, respectively, which is expected to provide a basis for FDA submission of pivotal trial designs, facilitating the path to market for new therapies.
- Market Expansion Plans: CNSide aims to cover 150 million US lives through multiple commercial payor agreements and secure Medicare and Medicaid coverage, targeting over 1,250 commercial orders annually to enhance market penetration.
- Innovative Test Launch: CNSide will introduce additional cerebrospinal fluid tumor characterization tests to enrich its platform, aiming to improve management for patients with leptomeningeal metastases and address the urgent need for novel therapies.
See More
Plus Therapeutics (PSTV) Provides Business Update with $16.6 Million Cash Position
- Business Update Announcement: Plus Therapeutics will deliver a business update on January 22, 2026, ahead of market open, followed by a conference call to discuss recent advancements in its precision radiotherapeutics program for CNS cancers, demonstrating the company's ongoing commitment to this field.
- Clinical Trial Progress: The company is actively conducting the ReSPECT-LM, ReSPECT-GBM, and ReSPECT-Pediatric CNS trials, targeting leptomeningeal metastases, recurrent glioblastoma, and pediatric brain tumors, indicating significant progress in developing radiopharmaceuticals for difficult-to-treat cancers.
- Strong Financial Position: As of Q3 2025, Plus Therapeutics reported $16.6 million in cash and cash equivalents, providing a solid financial runway for advancing its clinical and regulatory programs, showcasing effective financial management.
- Stock Performance Recovery: PSTV shares have traded between $0.16 and $2.31 over the past year, closing yesterday at $0.29, up 2.31%, and further rising to $0.33 in pre-market trading, up 14.12%, reflecting optimistic market sentiment towards the company's future prospects.
See More
Plus Therapeutics (PSTV) to Provide Business Update on January 22, 2026
- Business Update Announcement: Plus Therapeutics will provide a business update before market open on January 22, 2026, aimed at informing investors about recent developments and future plans to bolster market confidence.
- Conference Call Details: The management team will host a conference call at 9:00 AM ET on the same day, expected to discuss company strategy and product pipeline in detail, enhancing investor understanding of future growth prospects.
- Pipeline Progress: The company focuses on developing precision diagnostics and radiopharmaceuticals for central nervous system cancers, particularly in leptomeningeal metastases and recurrent glioblastoma, showing promising clinical potential.
- Role of Subsidiary CNSide: CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, is dedicated to developing laboratory tests to identify tumor cells that have metastasized to the central nervous system, further strengthening the company's competitive position in cancer management.
See More
Plus Therapeutics Study Shows Early Detection Can Reduce Healthcare Costs
- Economic Impact Analysis: Plus Therapeutics' study indicates that earlier diagnosis and therapeutic management of leptomeningeal metastases (LM) using the CNSide cerebrospinal fluid assay can reduce related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention and improved treatment precision, significantly alleviating the financial burden on patients.
- Clinical Data Support: The research highlights that late-stage LM patients incur median inpatient costs of about $20,000, with total related costs potentially exceeding $100,000 per month, underscoring the critical importance of early detection to lower healthcare expenditures and improve patient outcomes.
- Conference Presentation: The findings will be presented at the ISPOR 2026 Annual Meeting, which gathers global experts in health economics and outcomes research, further promoting the recognition of CNSide's clinical and economic value and facilitating its commercialization in the United States.
- Innovative Treatment Solutions: REYOBIQ, a novel radiotherapy targeting CNS tumors, offers enhanced targeting and safety, currently undergoing multiple clinical trials, demonstrating potential therapeutic advantages for difficult-to-treat cancers, thereby strengthening the company's competitive position in this sector.
See More
Plus Therapeutics Releases 2026 Milestones and Financial Results
- Financial Performance: Plus Therapeutics reported a FY GAAP EPS of -$0.29, beating expectations by $0.01, while revenue of $5.21M, down 10.5% year-over-year, still exceeded forecasts by $0.14M, indicating resilience amid challenges.
- Clinical Trial Progress: The company anticipates reporting optimal dosing and interval data for REYOBIQ in the ReSPECT-LM Phase 2 trial in Q3 2026, laying the groundwork for future clinical applications and enhancing market competitiveness.
- FDA Meeting Arrangement: Plus Therapeutics will complete enrollment in the ReSPECT-GBM Phase 2 trial and conduct an End of Phase meeting with the FDA, aiming to align on pivotal trial design, with data expected in Q4 2026 that could influence future drug approval processes.
- Manufacturing Scale-Up: The company plans to complete the commercial manufacturing scale-up for REYOBIQ and begin enrollment in the ReSPECT-PBC pediatric brain cancer Phase 1 trial, marking a strategic expansion into pediatric oncology and further strengthening its product portfolio.
See More
Plus Therapeutics Receives AMA Approval for New CPT Code
- CPT Code Approval: The American Medical Association has approved the CPT code X566T for tracking the use of REYOBIQ in recurrent glioblastoma and pediatric brain cancer, marking a significant advancement in market access for this innovative treatment, which is expected to enhance clinical application and reimbursement prospects.
- Clinical Trial Progress: Plus Therapeutics is on track to complete enrollment in its Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting to align on pivotal trial design, demonstrating the company's commitment to advancing clinical research.
- Funding Support: The clinical trials for REYOBIQ are supported by grants from the National Cancer Institute and a $17.6 million three-year grant from the Cancer Prevention & Research Institute of Texas, indicating strong recognition and backing from the research community.
- Market Potential: As a novel radiotherapy, REYOBIQ has the potential to improve treatment outcomes for CNS tumors, particularly where conventional therapies fail, further solidifying the company's market position in this critical area.
See More
Plus Therapeutics (PSTV) Outlines 2026 Goals to Advance REYOBIQ and Expand CNSide Platform
- Funding Support: Plus Therapeutics has completed a $15 million upsized offering aimed at accelerating the REYOBIQ clinical program and the commercialization of the CNSide diagnostic platform, thereby extending its cash runway through 2027 to ensure ongoing operations during critical development phases.
- Clinical Trial Progress: The REYOBIQ ReSPECT-LM and ReSPECT-GBM Phase 2 trials are set to report data in Q3 and Q4 2026, respectively, which is expected to provide a basis for FDA submission of pivotal trial designs, facilitating the path to market for new therapies.
- Market Expansion Plans: CNSide aims to cover 150 million US lives through multiple commercial payor agreements and secure Medicare and Medicaid coverage, targeting over 1,250 commercial orders annually to enhance market penetration.
- Innovative Test Launch: CNSide will introduce additional cerebrospinal fluid tumor characterization tests to enrich its platform, aiming to improve management for patients with leptomeningeal metastases and address the urgent need for novel therapies.
See More
Plus Therapeutics (PSTV) Provides Business Update with $16.6 Million Cash Position
- Business Update Announcement: Plus Therapeutics will deliver a business update on January 22, 2026, ahead of market open, followed by a conference call to discuss recent advancements in its precision radiotherapeutics program for CNS cancers, demonstrating the company's ongoing commitment to this field.
- Clinical Trial Progress: The company is actively conducting the ReSPECT-LM, ReSPECT-GBM, and ReSPECT-Pediatric CNS trials, targeting leptomeningeal metastases, recurrent glioblastoma, and pediatric brain tumors, indicating significant progress in developing radiopharmaceuticals for difficult-to-treat cancers.
- Strong Financial Position: As of Q3 2025, Plus Therapeutics reported $16.6 million in cash and cash equivalents, providing a solid financial runway for advancing its clinical and regulatory programs, showcasing effective financial management.
- Stock Performance Recovery: PSTV shares have traded between $0.16 and $2.31 over the past year, closing yesterday at $0.29, up 2.31%, and further rising to $0.33 in pre-market trading, up 14.12%, reflecting optimistic market sentiment towards the company's future prospects.
See More
Plus Therapeutics (PSTV) to Provide Business Update on January 22, 2026
- Business Update Announcement: Plus Therapeutics will provide a business update before market open on January 22, 2026, aimed at informing investors about recent developments and future plans to bolster market confidence.
- Conference Call Details: The management team will host a conference call at 9:00 AM ET on the same day, expected to discuss company strategy and product pipeline in detail, enhancing investor understanding of future growth prospects.
- Pipeline Progress: The company focuses on developing precision diagnostics and radiopharmaceuticals for central nervous system cancers, particularly in leptomeningeal metastases and recurrent glioblastoma, showing promising clinical potential.
- Role of Subsidiary CNSide: CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, is dedicated to developing laboratory tests to identify tumor cells that have metastasized to the central nervous system, further strengthening the company's competitive position in cancer management.
See More
